{Reference Type}: Journal Article
{Title}: Impact of molecular testing on the surgical management of advanced epithelial ovarian cancer.
{Author}: Colombo PE;Taoum C;Fabbro M;Quesada S;Rouanet P;Ray-Coquard I;
{Journal}: Crit Rev Oncol Hematol
{Volume}: 202
{Issue}: 0
{Year}: 2024 Oct 5
{Factor}: 6.625
{DOI}: 10.1016/j.critrevonc.2024.104469
{Abstract}: Ovarian carcinoma remains the most lethal gynaecologic malignancy. Half of all high-grade serous ovarian cancers (HGSOCs) have a homologous recombination deficiency (HRD) with regard to the repair of double-strand DNA breaks and are candidate to receive maintenance treatment with PARP inhibitors. While a wealth of literature exists regarding the therapeutic guidance of patients from a medical standpoint, the influence of the HRD status on the surgical outlook has been comparatively limited. In this review, the clinical and biological features of advanced ovarian cancers with BRCA1/2 mutation and/or HRD status are considered with particular reference to their impact on the surgical management and on the medico-surgical sequence. The modification of the surgical indications according to the results of molecular testing in first-line and recurrent settings are discussed.